Latest stories on SKBBY
Results from Phase III Study of Trastuzumab Botidotin versus T-DM1 in HER2-Positive Breast Cancer Published in JCO
PR Newswire63 · neutralproduct/pr
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 2026 Q2 - Results - Earnings Call Presentation
Seeking Alpha50 · neutralearnings
Kelun-Biotech Announces 2026 Interim Results
PR Newswire50 · neutralgeneral